<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi>, through stimulation of AT(1) receptors, not only controls blood pressure but also modulates cerebrovascular flow </plain></SENT>
<SENT sid="1" pm="."><plain>We sought to determine whether selective AT(1) <z:chebi fb="68" ids="48706">antagonists</z:chebi> could be therapeutically advantageous in <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> during <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We pretreated spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto controls with the AT(1) <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="3347">candesartan</z:chebi> (<z:chebi fb="0" ids="3347">CV-11974</z:chebi>), 0.5 mg/kg per day, for 3 to 14 days, via subcutaneously implanted osmotic minipumps </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed cerebral blood flow by laser-Doppler flowmetry, cerebral <z:hpo ids='HP_0001297'>stroke</z:hpo> in SHR after occlusion of the middle cerebral artery with reperfusion, and brain AT(1) receptors by quantitative autoradiography </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="3347">Candesartan</z:chebi> treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> pretreatment of SHR for 14 days partially prevented the decrease in blood flow in the marginal zone of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and significantly reduced the volume of total and cortical <z:mpath ids='MPATH_124'>infarcts</z:mpath> after either 1 or 2 hours of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> with reperfusion, relative to untreated SHR, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>This treatment also significantly reduced <z:hpo ids='HP_0002181'>brain edema</z:hpo> after 2 hours of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> with reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>In SHR, <z:chebi fb="0" ids="3347">candesartan</z:chebi> markedly decreased AT(1) binding in areas inside (nucleus of the solitary tract) and outside (area postrema) the blood-brain barrier and in the middle cerebral artery </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Pretreatment with an AT(1) <z:chebi fb="68" ids="48706">antagonist</z:chebi> protected hypertensive rats from <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> by normalizing the cerebral blood flow response, probably through AT(1) receptor blockade in cerebral vessels and in brain areas controlling cerebrovascular flow during <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>